Biotech giant Regeneron announced Monday that it would acquire DNA testing company 23andMe for $256 million following a bankruptcy auction. The deal includes access to 23andMe's massive personal and genetic data trove from more than 15 million customers.

Regeneron Pharmaceuticals said on Monday it will buy genetic testing firm 23andMe Holding for $256 million through a bankruptcy auction, and promised to prioritize the ethical use of customers' DNA data.